Connect with us

Hi, what are you looking for?

Stock

Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI

PARIS (Reuters) – France will take a stake in Sanofi (NASDAQ:SNY)’s Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper that U.S. private equity firm Clayton Dubilier & Rice (CD&R) is to take a 51% stake in the company that makes of one of France’s most-sold painkillers, Doliprane.

The plan for Public Investment Bank (BPI) to take a 1% stake in Opella, for about 150 million euros ($162.98 million), came through a tri-party agreement between Sanofi, the French state and CD&R and was approved by Sanofi’s board on Sunday, the newspaper said.

Finance minister Antoine Armand had said earlier this week that the government was looking at all options regarding Opella, including the state being on Opella’s board of directors.

($1 = 0.9204 euros)

This post appeared first on investing.com

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.






    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Editor's Pick

    Former president Donald Trump and his allies have filed hundreds of lawsuits, with more to come, seeking to tighten voting rules or disqualify voters....

    Economy

    LONDON (Reuters) – Bank of England interest rate-setter Megan Greene said she still believed the central bank should take a cautious approach to cutting...

    Economy

    Thousands of dockworkers on the East Coast and Gulf Coast will return to work after reaching a tentative agreement on wages, ending one of...

    Latest News

    Tunisians voted Sunday in an election expected to grant President Kais Saied a second term, as his most prominent detractors, including one of the candidates challenging...

    Disclaimer: beneficialinvestmentnow.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 beneficialinvestmentnow.com